TG Therapeutics (TGTX) Misses Q2 EPS by 4c
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of ($0.33), $0.04 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $30.1 thousand versus the consensus estimate of $40 thousand.
For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Gold (ABX) Tops Q3 EPS by 4c
- Antero Midstream Partners (AM) Tops Q3 EPS by 5c
- Raymond James Financial (RJF) Tops Q4 EPS by 29c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!